ArQule taps Beryllium as I/O discovery engine
This article was originally published in Scrip
Massachusetts biotech ArQule announced 05 May that is has teamed up with Beryllium Discovery on a research and development collaboration using ArQule's chemistry platform and the other company's discovery platform to pursue targets in immuno-oncology.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.